Immunotherapy of patients with multiple and extreme drug-resistant pulmonary tuberculosis with autologous monocyte- and stem cell-derived dendritic cells vaccine

• DOI: 10.1016/j.ijmyco.2014.11.033
• Publication Date: 2015-01-06T12:43:58Z
• Authors: L.P. Titov; A.Y. Hancharou; A.Y. Skrahin; V.V. Solodovnikova; A.M. Skrahina; N.S. Shpakovskaya; I.U. Ramanava; N.P. Antonova; A.M. Zalutskaya
• Keywords: CD86

This study evaluates the response of TB patients to treatment with autologous dendritic cell (DC) vaccine. There were 25 MDR⧹XDR pulmonary included in study. DCs obtained both from peripheral blood monocytes and bone marrow isolated stem cells using standard protocols. primed either M. tuberculosis lysates or CFP-10 peptides cultured maturation inducers. tested for immuno-phenotype, viability sterility injected into subcutaneously three times at 2- 3-week intervals. Clinical monitoring, sputum assessments, chest X-rays immune status performed before 2–3 months after treatment. The control group (C) consisted matched by sex age. all sterile, viable, morphologically intact phenotypically mature (expression CD83 CD86 being >80%). number averaged 10.2 (range: 8.3–15.6) × 106. Treatment was safe well tolerated. No significant side effects which required medical aid noted during combination DC-vaccination promoted decrease complete clearance mycobacteria (DC-treated – 69.23 ± 12.8% versus 30.76 C, p < 0.05) X-ray improvement (69.23 0.05). also associated increase antigen-specific T-cells blood, reflects accumulation indicates restoration against tuberculosis. DC-based may become an effective valuable method cellular immunotherapy MDR- XDR-TB patients.